Posted by divya sawant
Filed in Health 29 views
The acute pancreatitis market is experiencing steady expansion, driven by rising disease incidence, advancements in diagnostics and treatments, and increasing healthcare investments. According to The Insight Partners, the global acute pancreatitis market size was valued at US$ 5,649.77 million in 2022 and is projected to reach US$ 8,827.37 million by 2030, registering a CAGR of 5.7% during the forecast period.
Key Market Drivers
Several factors are fueling market growth. The rising prevalence of risk factors such as obesity, alcoholism, gallstones, diabetes, and certain medications has increased the global incidence of acute pancreatitis. In the United States alone, approximately 40–50 cases per 100,000 adults occur annually, resulting in nearly 275,000 hospital admissions.
A notable driver is the link between acute pancreatitis and subsequent diabetes. Damage to insulin-producing cells can lead to pancreatogenic diabetes. Studies indicate that around 23% of patients may develop diabetes within three years post-discharge, with acute pancreatitis accounting for a significant portion of such cases. This connection boosts demand for ongoing monitoring and related treatments.
Advancements in diagnostic technologies and novel therapies further propel the market. Improved imaging, biomarkers like fatty acid ethyl esters (FAEEs), genetic insights, and early nutritional interventions are enhancing patient outcomes. Awareness programs, such as those by the National Institutes of Health (NIH) through the Type 1 Diabetes after Acute Pancreatitis Consortium (T1DAPC), are addressing knowledge gaps and fostering innovation.
download the free sample report: https://www.theinsightpartners.com/sample/TIPRE00017674
The report segments the market by offerings, causes, end users, and geography.
By Offerings: The diagnosis segment held the largest share (56.5%) in 2022 due to the critical need for early and accurate detection. Urine tests dominated the diagnosis sub-segment with a 47.6% share. Medications and supportive care also play vital roles, with device-based therapies expected to grow fastest at a CAGR of 5.8%.
By Causes: Gallstones represent the leading and fastest-growing segment (projected CAGR of 6.1%), followed by alcoholism, genetic disorders, infections, and others. Gallstone-related cases drive substantial procedural and therapeutic demand.
By End User: Hospitals accounted for the dominant 75.1% share in 2022, as most acute cases require inpatient care. Diagnostic laboratories are anticipated to register the fastest growth, supported by outpatient testing advancements. Ambulatory surgical centers and other facilities complement the ecosystem.
North America dominated the market with a 56.8% share in 2022, thanks to high incidence rates linked to obesity and alcohol consumption, advanced healthcare infrastructure, and strong R&D presence. The US market is projected to grow at a CAGR of 5.6%.
Asia Pacific is poised for the highest regional CAGR of 7.4%, driven by improving healthcare access, rising awareness, lifestyle changes, and expanding patient pools in countries like China and India.
Europe, Middle East & Africa, and South & Central America also contribute, with varying growth influenced by local risk factors and infrastructure development.
Key players include Abbott Laboratories, GE HealthCare Technologies Inc., Samsung Healthcare, Koninklijke Philips NV, Baxter International Inc., Dynavax Technologies Corp., Actim Oy, Medtronic Plc, Boston Scientific Corp., and Fresenius Kabi AG. These companies focus on product innovation, clinical trials, partnerships, and portfolio expansion.
Recent highlights include:
Such developments signal a pipeline of targeted therapies that could transform management of moderate-to-severe cases.
Despite growth, challenges persist, including high treatment costs, limited specific therapies for severe cases, and diagnostic delays in some regions. However, opportunities abound in personalized medicine, AI-assisted diagnostics, biomarker research, and early intervention protocols.
The shift toward minimally invasive procedures, better nutritional support, and preventive strategies against risk factors (e.g., gallstone management and alcohol awareness) will shape the market. Collaborative research between academia, industry, and governments is expected to accelerate breakthroughs.
The acute pancreatitis market is on a robust growth trajectory, underpinned by epidemiological trends, technological progress, and heightened healthcare focus. With a projected value exceeding US$ 8.8 billion by 2030, stakeholders have strong incentives to invest in innovation and expanded access. Continued emphasis on early diagnosis, effective treatments, and post-acute care will be crucial for improving patient outcomes worldwide.
About The Insight Partners The Insight Partners delivers market intelligence and consulting services to help clients make informed decisions. The firm covers industries such as Aerospace and Defense, Automotive and Transportation, Semiconductor and Electronics, Biotechnology, Healthcare IT, Manufacturing, Medical Devices, Technology, Media, and Chemicals and Materials.
Contact Us
Email: sales@theinsightpartners.com
Website: www.theinsightpartners.com
Phone: +1-646-491-9876